Carmat
ALCAR
Company Profile
Business description
Carmat is a France-based company engaged in the development and production of heart prosthesis. It engages in the development of implantable orthotopic and biocompatible artificial heart organs for the treatment of heart failure patients. The company also develops the product's power supply system and its control and remote diagnosis systems.
Contact
36, avenue de l’Europe
Immeuble l’Etendard Energy III
Velizy Villacoublay78140
FRAT: +33 139456450
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
182
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks
Impact of ANZ’s huge fine
Working to prevent repeated failures could also improve competitiveness.
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,091.80 | 30.70 | -0.34% |
| CAC 40 | 7,818.22 | 78.71 | -1.00% |
| DAX 40 | 23,329.24 | 419.62 | -1.77% |
| Dow JONES (US) | 45,757.90 | 125.55 | -0.27% |
| FTSE 100 | 9,195.66 | 81.37 | -0.88% |
| HKSE | 26,812.19 | 373.68 | 1.41% |
| NASDAQ | 22,333.96 | 14.79 | -0.07% |
| Nikkei 225 | 44,915.67 | 13.40 | 0.03% |
| NZX 50 Index | 13,193.02 | 41.87 | -0.32% |
| S&P 500 | 6,606.76 | 8.52 | -0.13% |
| S&P/ASX 200 | 8,816.60 | 31.90 | -0.36% |
| SSE Composite Index | 3,877.55 | 15.68 | 0.41% |